For research use only. Not for therapeutic Use.
Alectinib(cas 1256580-46-7) is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth. Alectinib was approved in Dec. 2015.
Catalog Number | A000528 |
CAS Number | 1256580-46-7 |
Synonyms | Alectinib free base; 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile |
Molecular Formula | C₃₀H₃₄N₄O₂ |
Purity | ≥95% |
Target | ALK |
Solubility | Soluble in DMSO, not in water |
Storage | 3 years -20C powder |
InChI | InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3 |
InChIKey | KDGFLJKFZUIJMX-UHFFFAOYSA-N |
SMILES | CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6 |
Reference | 1: Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung |